AnaptysBio 3Q 2026: Revenue $30.27M, EPS $0.11 — 10-Q Summary

AnaptysBio reported 3Q 2026 revenue of $30.27M, down 60% YoY, and net income of $3.88M, down 74.4% YoY, due to the absence of a prior-year GSK milestone and higher costs. Jemperli royalties increased, while Zejula royalties declined. The company has $153M in cash and expects it to last at least 12 months.

Original reporting
Published Nov 12, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AnaptysBio 3Q 2026: Revenue $30.27M, EPS $0.11 — 10-Q Summary — source image
Decision brief

The 30-second read

$ANABBearishMed
01

Why it matters

The earnings miss signals short‑term weakness but the company retains sufficient cash for operations, leaving upside potential if pipeline milestones are achieved.

02

Market read

First‑report earnings for a US‑listed biotech; likely to move the stock on the downside.

03

What to watch

Cash balance of $153M provides runway, and higher Jemperli royalties could offset some revenue weakness.

Relevance 6/10Novelty 7/10Timing: after‑hours release

Background

AnaptysBio filed its Q3 2026 Form 10‑Q, highlighting a steep revenue decline after a prior $50M GSK milestone and increased litigation costs.

Company-level read

Ticker impact

$ANABBearishHigh confidence
Context

Q3 2026 10‑Q shows revenue down 60% YoY to $30.27M and EPS falling to $0.11, missing prior quarter.

Expected impact

likely pressure as the market prices in the revenue decline and missed milestone

Evidence & confidence

The disclosed numbers are the first public release of the quarter and represent a material downside versus the prior period.

Market effects

Biotech sector may see broader risk‑off pressure as a peer reports a sharp revenue drop.

US biotech investors may adjust exposure to early‑stage pipelines.

Limited; impact confined to US‑listed biotech space.

Counterpoint

The drop may be temporary if upcoming GSK milestones materialize, offering a buying opportunity at lower valuations.

Key entities

  • GSK

    Provided milestone and royalty revenue; no milestone recognized this quarter.

Related articles

$ANABHighAI 8/10

ANAPTYSBIO, INC (ANAB): Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAPTYSBIO, INC (ANAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update • Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth • Jemperli approved in the U.S. as

$ANABHighAI 9/10

AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.

$ANABHighAI 9/10

AnaptysBio (ANAB) Shares Rise After GSK's FDA Label Expansion fo

AnaptysBio (ANAB) shares rose after partner GSK received FDA approval for an expanded label of anti-PD-1 therapy Jemperli. The approval allows marketing for a new cancer indication, accelerating regulatory action. ANAB's P/E ratio is 7.64x, below its 5-year median. Insider activity shows net selling. ANAB's GF Score is 43/100, reflecting mixed fundamentals.

$ANABHighAI 8/10

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

AnaptysBio (ANAB) rose after partner GSK (GSK) received FDA approval to expand Jemperli's label for treating certain rectal cancers. The drug is now approved for adults with stage II/III MSI-H/dMMR locally advanced rectal cancer, a subset of 5%-10% of rectal cancers. The approval came earlier than the expected February 2027 date.